Fingerpaint, Knox Lane Partner for Fingerpaint’s “Next Stage of Growth”

SARATOGA SPRINGS — Knox Lane, a leading middle-market investment firm focused on the consumer and services sectors, announced on Dec. 16 a strategic investment in Fingerpaint. 

Founded by Ed Mitzen in 2008, Fingerpaint has provided integrated marketing services to a growing roster of healthcare clients, specifically in pharmaceutical, rare disease and gene therapy, resulting in 12 straight years of significant revenue growth and expansion. 

“We are pleased to welcome Knox Lane as Fingerpaint’s partner, and believe this investment is a testament to the strength of our platform,” said Mitzen, in a prepared statement. “Like our company, the Knox Lane team has a strong sense of culture and values. We look forward to leveraging their operational expertise and unique insights to execute on our shared growth initiatives and capitalize on new and exciting opportunities. Knox Lane is the ideal partner for Fingerpaint’s next stage of growth. This is an exciting day for our team and our clients.”

Fingerpaint employs more than 400 across its five offices in Saratoga Springs, New York, Pennsylvania, Arizona, New Jersey, and California. Financial terms of the transaction were not disclosed.

In February 2020, Fingerpaint enhanced its healthcare advisory capabilities through the acquisition of 1798, a market access and commercialization firm that specializes in healthcare consulting services, including patient and provider access services, financial impact analysis and analytics, competitive intelligence, and pull-through solutions.